Alflutinib Recruiting Phase 2 Trials for Multiple Primary Lung Cancers Treatment

IndicationsStatusPurposePhase
RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT04982900Treatment of EGFR-TKI for Residual Lesions of Multiple Synchronous Ground-glass Opacities